Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno

Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Brazel, Danielle, Ou, Sai-Hong Ignatius, Nagasaka, Misako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831070/
https://www.ncbi.nlm.nih.gov/pubmed/36636263
http://dx.doi.org/10.2147/LCTT.S379389
_version_ 1784867794221793280
author Brazel, Danielle
Ou, Sai-Hong Ignatius
Nagasaka, Misako
author_facet Brazel, Danielle
Ou, Sai-Hong Ignatius
Nagasaka, Misako
author_sort Brazel, Danielle
collection PubMed
description Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients.
format Online
Article
Text
id pubmed-9831070
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-98310702023-01-11 Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno Brazel, Danielle Ou, Sai-Hong Ignatius Nagasaka, Misako Lung Cancer (Auckl) Review Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III SKYSCRAPER-02 failed to find PFS or OS benefit in patients with SCLC. Atezolizumab was the first immunotherapy to show survival benefit in extensive SCLC based on the phase III IMpower133 study. Given that immunotherapy has become the standard of care for SCLC patients, further research is needed into ways to augment the immune system to better treat these patients. Dove 2023-01-05 /pmc/articles/PMC9831070/ /pubmed/36636263 http://dx.doi.org/10.2147/LCTT.S379389 Text en © 2023 Brazel et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Brazel, Danielle
Ou, Sai-Hong Ignatius
Nagasaka, Misako
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title_full Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title_fullStr Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title_full_unstemmed Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title_short Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno
title_sort tiragolumab (anti-tigit) in sclc: skyscraper-02, a towering inferno
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9831070/
https://www.ncbi.nlm.nih.gov/pubmed/36636263
http://dx.doi.org/10.2147/LCTT.S379389
work_keys_str_mv AT brazeldanielle tiragolumabantitigitinsclcskyscraper02atoweringinferno
AT ousaihongignatius tiragolumabantitigitinsclcskyscraper02atoweringinferno
AT nagasakamisako tiragolumabantitigitinsclcskyscraper02atoweringinferno

Ejemplares similares